Monday, 28 September 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange

Medplus Health Services Ltd

NSE: MEDPLUS · BSE: 543427 · Healthcare · 22 announcements

Share price
₹654.90
Market cap
₹7,868 Cr
Revenue (annual)
₹6,892 Cr
Net profit (annual)
₹219.7 Cr
P/E (TTM)
37.4×Sector 57.8×
Promoter holding
40.19%-0.03% QoQ
FII holding
14.38%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

19:09 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services' subsidiary, Optival Health Solutions, faced a three-day drug license suspension at a store by the Drugs Control Administration, impacting operations by ₹0.01 Crore.

Value
₹0.01 Cr
From
Drugs Control Administration, Haveri Circle, Karnataka
18:02 IST BSE
Legal & Regulatory

Medplus Health Services Legal & Regulatory

MedPlus Health Services' subsidiary, Optival Health Solutions, received a one-day drug license suspension from the Drugs Control Administration for a store in Telangana due to non-compliance.

Value
₹0.01 Cr
18:29 IST BSE
Legal & Regulatory

Medplus Health Services Legal & Regulatory

Medplus Health Services' subsidiary, Optival Health, received a 7-day drug license suspension in Andhra Pradesh and stay orders for previous suspensions in Maharashtra.

Value
₹0.02 Cr
17:11 IST NSE
Legal & Regulatory

Medplus Health Services Legal & Regulatory

Medplus Health Services disclosed that regulatory authorities suspended the drug licenses of five subsidiary stores for 3 to 7 days. The expected financial impact is ₹0.10 Crore.

Value
₹0.10 Cr
17:20 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services reported a 7-day drug license suspension for a subsidiary store, impacting its operations with an estimated financial loss of ₹0.02 Crore.

Value
₹0.02 Cr
Execution
7 days
13:56 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services' subsidiary, Optival Health Solutions, faced drug license suspensions for two stores from regulatory authorities, causing a total financial impact of Rs 0.0961 Crore.

Value
₹0.10 Cr
Execution
5 to 15 days
16:57 IST BSE
Legal & Regulatory

Medplus Health Services Legal & Regulatory

Medplus Health Services reported a 7-day drug license suspension for a subsidiary store in Chhattisgarh, estimating a financial impact of ₹0.01 Crore.

Value
₹0.01 Cr
17:07 IST NSE
Legal & Regulatory

Medplus Health Services Legal & Regulatory

Medplus Health Services reported a 5-day suspension of a drug license at a Mangalore store due to compliance issues. The expected financial impact is ₹0.03 Crore.

Value
₹0.03 Cr
17:07 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health Services' subsidiary, Optival Health Solutions, faced a five-day drug license suspension at its Kapikad store due to regulatory violations. The impact is Rs 0.03 Crore.

Value
₹0.03 Cr
suspension period
5.0 days
16:12 IST BSE
Legal & Regulatory

Medplus Health Services Legal & Regulatory

MedPlus Health Services has filed board comments regarding a fine levied by the exchanges for non-compliance with Regulation 17(1A) of SEBI LODR Regulations, 2015.

15:09 IST NSE
Acquisition

Medplus Health Services Acquisition Worth ₹1.1 Cr

MedPlus acquired the remaining 0.01% stake in Optival Health Solutions for Rs.1.10 Crore. This makes Optival a wholly owned subsidiary of MedPlus.

Value
₹1.10 Cr
13:21 IST BSE
Board Meeting Outcome

Medplus Health Services Board Meeting Outcome

Medplus approved acquiring the 0.01% residual stake in material subsidiary Optival Health Solutions for Rs.1.10 Crore. Optival's FY26 turnover of Rs.6,816 Crore will now be fully consolidated.

Value
₹1.10 Cr
17:21 IST NSE
Legal & Regulatory

Medplus Health Services Legal & Regulatory

Medplus Health's subsidiary received suspension notices for drug licenses at two stores. The combined financial impact is estimated at Rs 14.62 lakhs.

Value
₹0.15 Cr
17:21 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

Medplus Health's subsidiary faces temporary drug license suspensions at two store locations in Bangalore and Pune, resulting in an estimated financial impact of Rs 0.15 Crore.

Value
₹0.15 Cr
17:53 IST BSE
Adverse Business Impact

Medplus Health Services Adverse Business Impact

MedPlus's subsidiary faces a 7-day drug license suspension at a Maharashtra store, with an estimated financial impact of Rs 0.0175 Crore.

Value
₹0.02 Cr
Execution
7 days
16:09 IST BSE
Other Announcement

Medplus Health Services Other Announcement

Alka Ajit Rangnekar, an immediate relative of a director, acquired 3,725 equity shares via off-market transfer. The transaction value amounts to approximately ₹0.24 Crore.

Value
₹0.24 Cr